Redefining cancer treatment: the role of imatinib nanoparticles in precision medicine.

Abstract

The world faces cancer as one of its primary mortality factors hence scientists must continuously research for enhanced treatment methods. The treatments for gastrointestinal stromal tumors and chronic myeloid leukemia improve because patients can receive tyrosine kinase inhibitor imatinib which finds both BCR-ABL fusion protein and other tyrosine kinases. Traditional administration of imatinib produces a range of negative effects due to systemic toxicity along with resistance development and absorption and solubility limitations. Medical compounds delivered through nanotechnology show promising qualities because they offer both improved targeting precision and better dissolving efficiency and longer drug residence time and reduced side effects. Medical applications of imatinib become stronger when the medication transforms into nanoparticles including liposomes and solid lipid nanoparticles (SLNs) and polymeric nanoparticles and dendrimers and micelles because these mixed nanoparticles decrease treatment side effects. The EPR effect allows the regulation of nanocarrier uptake alongside drug release to achieve improved medicine distribution within tumors. This paper examines contemporary advancements in cancer therapy that employs nanoparticles containing imatinib medication. The research presents diverse nanoparticulate formulations with production techniques together with a detailed explanation of their working mechanisms. The content discusses approaches to create imatinib nanoformulations for advanced cancer therapy through future investigations and how nanoparticles can tackle drug delivery problems.